skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Impact of olmesartan on blood pressure, endothelial function, and cardiovascular outcomes

Review

(1697) Views  (532) Full article downloads

Authors: Eduardo Pimenta, Suzanne Oparil

Published Date September 2010 Volume 2010:3 Pages 113 - 123
DOI: http://dx.doi.org/10.2147/IBPC.S11717

Eduardo Pimenta1, Suzanne Oparil2
1Endocrine Hypertension Research Centre and Clinical Centre of Research Excellence in Cardiovascular Disease and Metabolic Disorders, University of Queensland School of Medicine, Princess Alexandra Hospital, Brisbane, Queensland, Australia; 2Vascular Biology and Hypertension Program, University of Alabama at Birmingham, Birmingham, AL, USA

Abstract: The vascular endothelium, the largest “organ” in the body, synthesizes and releases a wide spectrum of vasoactive substances into the circulation. Endothelial dysfunction links hypertension and other cardiovascular (CV) risk factors that promote the development of atherosclerotic plaque, CV disease, and fatal and nonfatal CV events. Blood pressure (BP) reduction is the most effective way to reduce CV risk in patients with hypertension, but it is unknown whether endothelial dysfunction is a cause or consequence of hypertension. Renin–angiotensin–aldosterone system blockers improve endothelial function and have favorable vascular, metabolic, cardiac, and renoprotective effects that are independent of BP reduction. Olmesartan effectively reduces BP and also has vasoprotective properties, including reductions in endothelial dysfunction and inflammation, prevention of microalbuminuria, and reversal of vascular remodeling. Large-scale, long-term studies are needed to confirm that olmesartan has vasoprotective effects that are independent of BP control and to determine whether these pleiotropic effects translate into improved CV disease outcomes.

Keywords: hypertension, endothelial function, cardiovascular outcomes, olmesartan






Readers of this article also read:

Antihypertensive effects of astaxanthin
Impact of dyslipidemia on cardiovascular risk stratification of hypertensive patients and association of lipid profile with other cardiovascular risk factors: results from the ICEBERG study
Cuff inflation during ambulatory blood pressure monitoring and heart rate
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Current concepts in combination therapy for the treatment of hypertension: combined calcium channel blockers and RAAS inhibitors
Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness
Reappraisal of role of angiotensin receptor blockers in cardiovascular protection
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University